[Methylation of the factor IX gene--a basic reason for the mutation causing hemophilia B]

Area of Science:

• Genetics
• Molecular Biology
• Biochemistry

Context:

• Haemophilia B is a genetic bleeding disorder caused by mutations in the factor IX gene.
• Understanding the molecular mechanisms underlying these mutations is crucial for developing effective therapies.
• Previous studies have identified various mutation types, but the role of DNA methylation remains under investigation.

Purpose:

• To analyze the contribution of DNA methylation to mutations in the factor IX gene.
• To identify specific mutation 'hot spots' associated with methylation.
• To propose therapeutic strategies targeting gene methylation for haemophilia B.

Summary:

• Analysis of 750 mutations in the factor IX gene of 806 haemophilia B patients revealed that 40% of point mutations occur in methylated CpG sites.
• These CpG mutations, primarily CG to TG or CA transitions, are attributed to m5C deamination and G/T-mismatch repair errors, leading to de novo mutations.
• Overall, CpG methylation contributes to 50% of factor IX gene mutations, with these sites mutating 48 times more frequently than others.
• Newly formed CpG sites and methylated CTCG sites also contribute significantly to mutations.
• It is estimated that 50-70% of all human gene mutations may result from gene methylation.

Impact:

• Identifies DNA methylation as a major driver of factor IX gene mutations in haemophilia B.
• Highlights CpG sites as critical mutation hotspots.
• Suggests that protecting the factor IX gene from methylation could be a novel therapeutic strategy for haemophilia B.